"He goes for the lowest hanging fruit (and the least amount of money) hoping for an EUA or BTD and he sells it to shareholders in that manner."
Now that sounds like good business sense. Going after low hanging fruit that can add the quickest, and highest, value to our product. Nice job of explaining the dynamics of Cytodyn, Leronlimab, and Nader Pourhassan.
Dr Harish , Dr Lalezari , Dr Yang , asking FDA for 4 doses for CD12 was not a miserable team , but a top line of a doctors who treated patients with Leronlimab , and knew what they are talking about , in contrary to FDA ..